Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for renal protection in heart failure and pulmonary hypertension
NCT01960153Phase 3Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2013
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tadalafil in heart failure (HF), pulmonary hypertension (PH), sponsored by Massachusetts General Hospital. Planned start Oct 2013; status: withdrawn.
02
Drugs
tadalafil
03
Conditions
heart failure (HF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT01960153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01960153.